SIDE EFFECTS
Associated with Discontinuation of Treatment
Nineteen percent (537/2897) of venlafaxine patients in Phase 2 and Phase 3 depression studies discontinued treatment due to an adverse event. The more common events ³1%) associated with discontinuation and considered to be drug-related (ie, those events associated with dropout at a rate approximately twice or greater for venlafaxine compared to placebo) included:
CNS |
Venlafaxine |
Placebo |
Somnolence |
3% |
1% |
Insomnia |
3% |
1% |
Dizziness |
3% |
¾ |
Nervousness |
2% |
¾ |
Dry mouth |
2% |
¾ |
Anxiety |
2% |
1% |
Gastrointestinal |
||
Nausea |
6% |
1% |
Urogenital |
||
Abnormal ejaculation* |
3% |
¾ |
Other |
||
Headache |
3% |
1% |
Asthenia |
2% |
¾ |
Sweating |
2% |
¾ |
